Showing 3721-3730 of 4164 results for "".
- Aurion Announces Positive Topline Data for Phase 1/2 Trial of Allogeneic Cell Therapy for Corneal Edemahttps://modernod.com/news/aurion-announces-positive-topline-data-for-phase-12-trial-of-allogeneic-cell-therapy-for-corneal-edema-secondary-to-corneal-endothelial-dysfunction/2482584/Aurion Biotech announced topline data from its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy product candidate for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product candidate comprise
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely
- Atsena Completes Dosing in Part A of Phase 1/2 Trial Evaluating Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-completes-dosing-in-part-a-of-phase-12-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482579/Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.S
- Sepul Bio Announces First Patient Dosed in Trial Using Ultevursen for RPhttps://modernod.com/news/sepul-bio-annouces-dosage-of-first-participant-in-clinical-trial-using-ultevursen-for-retinitis-pigmentosa-treatment/2482578/Sepul Bio announced the first person has been dosed for the LUNA clinical study, a phase 2b trial using ultevursen for USH2A-associated retinitis pigmentosa (RP). USH2A, or Usher Syndrome type 2a, is the most common cause of autosomal recessive retinitis pigmentosa that affec
- EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMDhttps://modernod.com/news/eyepoint-announces-first-patient-dosed-in-phase-3-lucia-trial-of-duravyu-for-wet-amd/2482563/EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD). Duravyu is an inves
- Ocugen Reports Positive Preliminary Data from OCU410 Trial for Geographic Atrophyhttps://modernod.com/news/ocugen-reports-positive-preliminary-data-from-ocu410-trial-for-geographic-atrophy/2482550/Ocugen announced encouraging preliminary results from the phase 1 portion of its phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The trial, which includes nine patients across three dose cohorts, revealed promis
- MediPrint Ophthalmics Unveils Phase 2b Trial Results for Drug-Eluting Contact Lens in Glaucoma Treatmenthttps://modernod.com/news/mediprint-ophthalmics-unveils-phase-2b-trial-results-for-drug-eluting-contact-lens-in-glaucoma-treatment/2482539/MediPrint Ophthalmics announced positive results from its phase 2b clinical trial of its 3D-printed, drug-eluting contact lens LL-BMT1. The results, presented by Ian Ben Gaddie, OD, FAAO, at the Ameri
- Ocular Therapeutix Names Namrata Saroj as Chief Business Officerhttps://modernod.com/news/ocular-therapeutix-names-namrata-saroj-as-chief-business-officer/2482536/Ocular Therapeutix announced that Namrata Saroj, OD, has joined the company as Chief Business Officer (CBO). Dr. Saroj, who has been consulting with Ocular since February 2024, brings extensive experience in clinical development and commercialization in ophthalmology. She cont
- Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/Tarsus Pharmaceuticals announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor s
- New Partnership to Boost Access to Specialist Eye Care and Related Research for Patients Across the USAhttps://modernod.com/news/new-partnership-accelerates-access-to-critical-vision-care-in-ird-trials/2482524/A new partnership will offer seamless, end-to-end solutions that will drive progress in both patient care and research outcomes in inherited retinal diseases (IRD). The collaboration between genomics and clinical trials specialist Sano Genetics, 20/20 Onsite, and concierge pa